We also showed that treatment with the CK2 inhibitor, TBB, which can restore/enhance Ikaros function, could increase IKZF1 binding at the CRLF2 promoter and suppress CRLF2 expression in both ALL cell lines and primary cells in an IKZF1 dependent manner. Here, CRLF2 is linked to acute lymphoblastic leukemia.